Skip to content
Research Article Open access CC BY 4.0

Facial Itching with Missed Doses of Vilazodone

Tracy L. Skaer, Amanda C. Helmann, Edith Ward

International Journal of Medical and Pharmaceutical Case Reports · pp. 1–5 · Published 6 May 2016

10.9734/IJMPCR/2016/25831

Abstract

Aims: Our aim is to describe a case of moderate to severe facial itching associated with missed doses of vilazodone. Presentation of Case: This report concerns a 53-year old woman with systemic lupus erythematosus and major depressive disorder who experienced sporadic episodes of moderate to severe facial itching around her eyes, cheeks, and forehead after she was prescribed vilazodone. Discussion: Investigation into the potential causes of the reaction determined that it was not consistent with a SLE malar rash, photosensitivity, hydroxychloroquine-induced lichenoid eruption, or menopausal-related dry skin. The facial pruritus did not respond to antihistamine pharmacotherapy. Symptoms always recurred following missed doses and resolved immediately within 90 minutes after taking the vilazodone. Full compliance with vilazodone has eliminated any further facial itching symptoms. Conclusion: The authors conclude that vilazodone is the most likely source of the intense pruritus. The reaction occurred consistently after missed doses of the medication and other potential causes were ruled out. This case provides important evidence for health care practitioners to utilize when monitoring and educating of their patients about vilazodone.

Vilazodone facial itching withdrawal symptom nonadherence treatment emergent adverse effect.

References (16)

  1. 1 Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication [DOI]
  2. 2 The Costs of Depression [DOI]
  3. 3 Estrogen and skin: The effects of estrogen, menopause, and hormone replacement therapy on the skin [DOI]
  4. 4 Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus [DOI]
  5. 5 The burden of recurrent depression: causes, consequences, and future prospects.
  6. 6 Lichenoid drug eruptions [DOI]
  7. 7 Common mental disorders and psychological distress in systemic lupus erythematosus are not associated with disease activity [DOI]
  8. 8 Reasons for Antidepressant Nonadherence Among Veterans Treated in Primary Care Clinics [DOI]
  9. 9 Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder [DOI]
  10. 10 Prevalence of depression and depressive symptoms in patients with systemic lupus erythematosus: Iranian experience [DOI]
  11. 11 Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis) [DOI]
  12. 12 Menopausal symptoms: Do life events predict severity of symptoms in peri- and post-menopause? [DOI]
  13. 13 Prevalence and predictors of depression in patients with systemic lupus erythematosus: a cross-sectional study [DOI]
  14. 14 Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy [DOI]
  15. 15 Vilazodone [DOI]
  16. 16 Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus [DOI]

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

12

Page views

0

PDF downloads

1

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.